Veracyte, Inc. (NASDAQ: VCYT) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Veracyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $24.08, Veracyte, Inc. trades at 15.2x trailing earnings, 3.4x sales and 1.4x book value, with an EV/EBITDA of 13.5. Over the last twelve months it generated about $580M of revenue and $128M of net income. It runs a gross margin of 72.3%, an operating margin of 15.4% and a net margin of 21.8%. It shows return on equity of 9.3%, return on invested capital of 6.0% and a free cash flow yield of 8.3%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.56. Over the past 52 weeks the share price ranged from $21.91 to $60.91, with a beta of 1.96.
Veracyte, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 14 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Veracyte, Inc. (VCYT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.1% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.1% / 33% · Receivables / Mkt Cap (36m) 1.70% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.1% / 33.33% · Receivables / Mkt Cap (24m) 1.70% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 28.9% / 33.33% · Receivables / Avg Assets (4Q) 3.49% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 23.6% / 33.33% · (Cash+Recv) / Total Assets 27.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Veracyte, Inc. (VCYT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Veracyte, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Veracyte, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.